15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.
Status:
Completed
Trial end date:
2007-08-04
Target enrollment:
Participant gender:
Summary
Subjects will be screened within 28 days, Simvastatin dose and single SB-649868 dose 10 and 7
days prior to repeat dosing respectively, 15 days SB-649868 repeat dosing with safety and
cognition function tests.